ROS1 and non-small cell lung carcinoma: This case report clearly demonstrates that cabozantinib achieved a durable clinical benefit of 12 months in a patient with advanced NSCLC who developed resistance to lorlatinib mediated by the ROS1 L2086F mutation.This outcome significantly exceeds the expected survival in this refractory patient population and provides important clinical insights.